These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1022953)

  • 41. Colchicine in the treatment of type 2 lepra reaction.
    Sharma VK; Kumar B; Kaur I; Singh M; Kaur S
    Indian J Lepr; 1986; 58(1):43-7. PubMed ID: 3745996
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary report.
    Balraj V; Jesudasan K; Chacko CJ; Christian M; Taylor PM; Fritschi EP; Job CK
    Int J Lepr Other Mycobact Dis; 1980 Dec; 48(4):397-401. PubMed ID: 7193654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study of erythema nodosum leprosum].
    Nguyen VU
    Ann Dermatol Venereol; 1994; 121(2):194-6. PubMed ID: 7979039
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [101 cases of lepromatous leprosy under observation without treatment after stable negativation. Evaluation 20 years later].
    Mugnier P; Rollier M; Rollier R
    Acta Leprol; 1982; (86-87):185-8. PubMed ID: 6815987
    [No Abstract]   [Full Text] [Related]  

  • 45. [Inflammatory tuberculoid leprosy and borderline leprosy treated with long-acting sulfamides (fanasil). Clinical, bacteriologic and immunologic changes in vivo and in vitro followed for 18 to 36 months].
    Saint-André P; Ferraci C; Baquillon G; Travi Piacentile M
    Acta Leprol; 1979; (76-77):315-7. PubMed ID: 121852
    [No Abstract]   [Full Text] [Related]  

  • 46. Effect of levamisole on clinical outcome and DNCB conversion in leprosy patients. A long term study.
    Yagnik CS; Jogaikar DG; Mehta JM
    Lepr India; 1983 Jan; 55(1):68-70. PubMed ID: 6680021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
    Jing Z; Zhang R; Zhou D; Chen J
    Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Leprosy. XI. Evaluation of thymus-derived lymphocytes by an antihuman T-lymphocyte antiserum.
    Lim SD; Touraine JL; Storkan MA; Choe YS; Good RA
    Int J Lepr Other Mycobact Dis; 1974; 42(3):260-5. PubMed ID: 4549214
    [No Abstract]   [Full Text] [Related]  

  • 49. A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
    Garraud O; Ribierre O; Bach MA
    Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):38-45. PubMed ID: 2940306
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
    Sapkota BR; Shrestha K; Pandey B; Walker SL
    Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
    Sampaio EP; Malta AM; Sarno EN; Kaplan G
    Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Immuno-allergic accidents with rifamipcin].
    Flageul B; Wagner L; Cottenot F
    Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Risk factors for erythema nodosum leprosum.
    Manandhar R; LeMaster JW; Roche PW
    Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Vitamin E as protective agent against hemolysis in leprosy patients under dapsone treatment].
    Lardo MM; Díaz NB; Artaza JR; Carbia CD; Nazer R; Valdez R
    Medicina (B Aires); 1997; 57(2):150-4. PubMed ID: 9532824
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of drug treatment on electroneurological measures of peripheral nerve function in leprosy patients.
    Mendis S; Somasiri KG; Chularatna W
    Ceylon Med J; 1993 Dec; 38(4):174-7. PubMed ID: 8143332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chemotherapeutic trials in leprosy. 3. Pilot trial of a riminophenazine derivative. B.663, in the treatment of lepromatous leprosy.
    Pettit JH; Rees RJ; Ridley DS
    Int J Lepr Other Mycobact Dis; 1967; 35(1):25-33. PubMed ID: 5336368
    [No Abstract]   [Full Text] [Related]  

  • 57. Serum lysozyme in leprosy.
    Naik SS; Gurnani S
    Lepr India; 1980 Oct; 52(4):501-7. PubMed ID: 7464056
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of a trial of dapsone vs placebo in lepromatous leprosy.
    Levy L; Murray LP
    Int J Lepr Other Mycobact Dis; 1967; 35(3):393-4. PubMed ID: 4917111
    [No Abstract]   [Full Text] [Related]  

  • 59. Dapsone induced hypohaptoglobinemia in lepromatous leprosy patients.
    Sritharan V; Bharadwaj VP; Venkatesan K; Girdhar BK
    Int J Lepr Other Mycobact Dis; 1981 Sep; 49(3):307-10. PubMed ID: 7198620
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histoid leprosy: a retrospective study of 40 cases from India.
    Kaur I; Dogra S; De D; Saikia UN
    Br J Dermatol; 2009 Feb; 160(2):305-10. PubMed ID: 19016704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.